Two antiviral drugs, oseltamivir and zanamivir, are highly effective when given as a preventive measure to reduce the spread of the influenza virus.
The first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began on December 21, 2006, when the vaccine was administered to the first volunteer at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. Scientists from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), one of the NIH Institutes, designed the vaccine. The vaccine does not contain any infectious material from the influenza virus.
It sounds like the stuff of a campy ’50s horror movie (“It Came from the Ice!”), but a Bowling Green State University biologist believes it’s a very real possibility.
The UK Government has rejected claims that millions of elderly and infirm people are being put at risk of contracting potentially life-threatening flu because of problems distributing the vaccine.